
Pfizer’s Paxlovid study fails to answer key questions over benefit for broader populations
Pfizer said Tuesday that a much-watched study of its antiviral Paxlovid in patients who have Covid but don’t have risk factors for severe disease failed to show a benefit in …
Read More